Florida Atlantic University recently announced the launch of the MaryLynn Magar Fellowship at the Max Planck Academy at FAU’s John D. MacArthur Campus in Jupiter.
Month: November 2018
FLOSPINE ANNOUNCES THE COMMERCIAL LAUNCH OF ITS CANAVERAL®MINIMALLY INVASIVE PEDICLE SCREW SYSTEM
BOCA RATON, FL — FloSpine, a medical device company that designs, develops and manufactures spinal implants and instruments for the surgical treatment of spinal disorders, announced today the commercial launch of its CANAVERAL®Minimally Invasive Pedicle Screw System.
INNOVATIVE STROKE TREATMENT LEADS TO PATENT APPLICATIONS
Stroke is the third leading cause of death and disability in the United States, with one person dying every four minutes. Nearly 800,000 people have a stroke each year and about 87 percent are ischemic strokes, where blood flow to the brain is constrained or clogged. While there have been significant strides made in stroke research as well as major advances in stroke care, effective treatments are still insufficient and require a continued quest for new remedies. Current drugs designed for stroke intervention and treatment are based on their anti-oxidative properties or blockers of calcium channels or glutamate receptors. However, no clinically effective therapeutic intervention for stroke has yet been developed.
MORE “INNOVATIVE STROKE TREATMENT LEADS TO PATENT APPLICATIONS”
FAU AND MAX PLANCK LAUNCH FIRST-OF-ITS-KIND ACADEMY
FAMILIES AID DISCOVERY OF A SENSORY-PROCESSING DISORDER GENE IN CHILDREN WITH AUTISM TRAITS
JUPITER, FL— A concerned Texas mom finally has answers about the cause of her son’s sensory-processing problems thanks to a special collaboration among her patient-advocacy group and the lab of Scripps Research Neuroscientist Gavin Rumbaugh, PhD.
MORE “FAMILIES AID DISCOVERY OF A SENSORY-PROCESSING DISORDER GENE IN CHILDREN WITH AUTISM TRAITS”
THERAPEUTICSMD LEASES NEW HEADQUARTERS SPACE IN BOCA RATON
Women’s health-care product developer TherapeuticsMD has leased more than 56,000 square feet of office space in a new location in Boca Raton for its headquarters.
MORE “THERAPEUTICSMD LEASES NEW HEADQUARTERS SPACE IN BOCA RATON”
A NEW TREATMENT FOR ALZHEIMER’S? IT STARTS WITH LIFESTYLE
Sally Weinrich knew something was terribly wrong. On two separate occasions, she forgot to pick up her grandkids from school, and she kept mixing up their names. The 70-year-old retired nursing professor had to face reality. Her worsening symptoms — the forgetfulness and confusion, the difficulties communicating and organizing activities — weren’t just stress or the normal wear and tear of aging. She lived in a matchless setting, on a lake in South Carolina, nestled in a bucolic wood. She swam daily and kayaked three days a week. But even her purposefully healthy lifestyle couldn’t protect her from the darkness she feared most: Alzheimer’s disease.
MORE “A NEW TREATMENT FOR ALZHEIMER’S? IT STARTS WITH LIFESTYLE”
PALM BEACH COUNTY UNEMPLOYMENT RATE STAYS AT 12-YEAR LOW OF 3.1 PERCENT
West Palm Beach, Fla. (Nov. 16, 2018) – Palm Beach County job seekers have many reasons to be thankful this holiday season, according to the latest monthly reports released today by CareerSource Palm Beach County and the Florida Department of Economic Opportunity (all numbers not seasonally adjusted).
MORE “PALM BEACH COUNTY UNEMPLOYMENT RATE STAYS AT 12-YEAR LOW OF 3.1 PERCENT”
F1 ONCOLOGY’S INTERNATIONAL AFFILIATE, EXUMA BIOTECHNOLOGY, ANNOUNCES ACQUISITION OF STRATEGIC CAR-T ASSETS
SHANGHAI and WEST PALM BEACH, Fla., Nov. 13, 2018 — F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, today announced that its international affiliate, EXUMA Biotechnology Hong Kong, has formed Shanghai EXUMA Biotechnology Co., Ltd., a wholly foreign-owned enterprise (WFOE), to acquire all rights to novel chimeric antigen receptor T (CAR-T) cell therapy and manufacturing assets in Shanghai and Shenzhen for the development and commercialization of cellular therapies in Greater China to be used in the treatment of solid tumor malignancies.Shanghai EXUMA will develop these clinical programs into multicenter trials under a centralized regulatory pathway based on the results of investigator-initiated trials (IITs) of CAR-T therapies for the treatment of metastatic renal cell carcinoma (mRCC) and other solid tumor malignancies.
SCRIPPS – SYMPOSIUM NOVEMBER 27-18
Register for Scripp’s symposium in November 2018.
